Hi Mozz, I came up a question the other day when I review the clinic trial design of PARA_002. Appreciate if you or anyone else know the answers.
In order to get FDA approved, do we need to meet all secondary endpoints of PARA_002? (there are 22 seconday endpoints, do we need to get statistically significant p<0.05 at all timepoints in the trial up to day168?)
Or we only need to meet the key secondary endpoints (specfically it is function at day53, pain and function at day 84, p value <0.05)?
https://clinicaltrials.gov/ct2/show/NCT04809376?term=pentosan&cntry=AU&draw=2&rank=2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.015(3.90%) |
Mkt cap ! $153.8M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 40.0¢ | 37.0¢ | $108.2K | 280.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3187 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 66280 | 7 |
View Market Depth
| Last trade - 11.05am 03/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |